Financial Performance - For the nine months ended December 31, 2022, the group's revenue was approximately HKD 154.0 million, a decrease of 12.2% compared to HKD 175.5 million for the same period in 2021[7]. - The net profit for the nine months ended December 31, 2022, was approximately HKD 2.1 million, down 83.3% from HKD 12.6 million in the same period of 2021[7]. - The group's pre-tax profit was HKD 2.23 million, down 81.7% from HKD 12.22 million in the previous year[9]. - The total comprehensive income for the period was HKD 2.1 million, a significant decrease from HKD 12.57 million in the same period last year[9]. - Basic earnings per share decreased to HKD 0.26 from HKD 1.57, a decline of 83.4%[9]. - Revenue for the nine months ended December 31, 2022, was approximately HKD 154.0 million, a decrease of about HKD 21.5 million or 12.3% compared to HKD 175.5 million in the same period of 2021[33]. - The profit for the nine months ended December 31, 2022, was approximately HKD 2.1 million, down from HKD 12.6 million in the same period of 2021[33]. - Revenue from treatment services was HKD 150.9 million for the nine months ended December 31, 2022, compared to HKD 170.4 million in 2021, reflecting a decline of approximately 11.4%[19]. Costs and Expenses - The group's cost of inventory and consumables was HKD 19.2 million, compared to HKD 29.2 million in the prior year, reflecting a decrease of 34.3%[9]. - Employee costs increased to HKD 62.97 million from HKD 56.83 million, representing an increase of 10.5% year-on-year[9]. - Depreciation of property, plant, and equipment rose to HKD 19.4 million from HKD 13.1 million, an increase of 48.0%[9]. - The company’s marketing and promotion expenses for the nine months ended December 31, 2022, were HKD 14.3 million, down from HKD 20.6 million in 2021[22]. - Total other expenses decreased to approximately HKD 33.1 million for the nine months ended December 31, 2022, from HKD 39.6 million in the same period of 2021, mainly due to reduced promotional activities[45]. - The company’s depreciation expenses for property, plant, and equipment increased to HKD 19.4 million in 2022 from HKD 13.1 million in 2021[22]. - Inventory and consumables cost for the nine months ended December 31, 2022, was approximately HKD 19.2 million, down from HKD 29.2 million in the same period of 2021, reflecting a decrease in revenue[37]. Dividends - The board of directors did not recommend any dividend for the nine months ended December 31, 2022, consistent with the previous year[7]. - The company did not declare any dividends for the nine months ended December 31, 2022, consistent with the same period in 2021[26]. - The board did not recommend any dividend distribution for the nine months ended December 31, 2022, consistent with the same period in 2021[47]. Government Support - The company received government subsidies amounting to HKD 4.7 million during the nine months ended December 31, 2022[22]. - Other income increased to approximately HKD 5.1 million for the nine months ended December 31, 2022, compared to HKD 0.4 million in the same period of 2021, primarily due to government subsidies received under the anti-epidemic fund[39]. Corporate Governance - The company has maintained compliance with corporate governance codes and continues to review its practices to ensure adherence[49]. - The audit committee has reviewed the unaudited consolidated results for the nine months ended December 31, 2022, and confirmed compliance with applicable accounting standards and regulations[52]. Shareholder Information - As of December 31, 2022, major shareholders, including Mr. Ye and Ms. Fu, hold 514.5 million shares, representing 64.31% of the company[55]. - No stock options have been granted, exercised, or canceled under the stock option plan since its adoption, and there are no unexercised stock options as of December 31, 2022[62]. - The stock option plan aims to attract, retain, and reward qualified individuals contributing to the group, enhancing the interests of the company and its shareholders[62]. - There are no arrangements made for directors to acquire shares or debt securities of the company or any other corporation, nor have any rights been granted to directors or their immediate family members[64]. - No directors or their associates are engaged in any business that directly or indirectly competes with the group as of December 31, 2022[65]. Business Expansion - The company opened a flagship center in Mong Kok in May 2021 and a new center in Tsim Sha Tsui in June 2022 to expand its operations[32]. - The company plans to leverage its strong customer base and reputation to drive steady business growth and maximize shareholder value in the future[35]. Impact of COVID-19 - The group recorded a net profit of approximately HKD 2.1 million for the nine months ended December 31, 2022, down from HKD 12.6 million in the same period of 2021, primarily due to the impact of COVID-19 and the temporary closure of medical beauty centers[46].
亮晴控股(08603) - 2023 Q3 - 季度财报